History of current non-insulin medications for diabetes mellitus

References

• Levine R. Sulfonylureas: Background and development of the field. Diabetes Care. 1984; 7(Suppl 1): 3–7.
   Google Scholar
• Seltzer H. Efficacy and safety of oral hypoglycemic agents. Annual Review of Medicine. 1980; 31: 261–72. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Diabeta [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 29 February 2012].
   Google Scholar
• Micronase [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails[cited 29 February 2012].
   Google Scholar
• Glucotrol [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 29 February 2012].
   Google Scholar
• Kreisberg R. The second-generation sulfonylureas: Change or progress?. Annals of Internal Medicine. 1985; 102: 125–6.
   Web of Science ®Google Scholar
• Amaryl [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 29 February 2012].
   Google Scholar
• Bailey C, Day C. Metformin: Its botanical background. Pract Diab Int. 2004; 21: 115–7. 10.3402/jchimp.v2i3.19081.
   Google Scholar
• Brunton L, Lazon J, Parker K. Goodman and Gilman's the pharmacological basis of therapeutics11th ed. McGraw-Hill. New York, 2006
   Google Scholar
• Witters L. The blooming of the French lilac. J Clin Invest. 2001; 108: 1105–7.
   PubMed Web of Science ®Google Scholar
• UK Prospecitve Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837–53.
   Web of Science ®Google Scholar
• Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al.. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13(Suppl 1): 1–68.
   PubMedGoogle Scholar
• Misbin R. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004; 27: 1791–3. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr. 2010; 91: 262S–6S. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• FDA significantly restricts access to the diabetes drug Avandia [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226975.htm [cited 27 January 2012].
   Google Scholar
• Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CPJ, et al.. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care. 2011; 34: 916–22. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011; 34: 1369–71. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Prandin [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 27 January 2012].
   Google Scholar
• Starlix [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 27 January 2012].
   Google Scholar
• Precose [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: h\ttp://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 10 January 2012].
   Google Scholar
• Glyset [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 27 January 2012].
   Google Scholar
• Drucker D. Minireview: The glucagon-like peptides. Endocrinology. 2001; 142: 521–7. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009; 94: 1843–52. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Holst JJ. Glucagon-like peptide-1: From extract to agent. The claude bernard lecture, 2005. Diabetologia. 2006; 49: 253–60. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267: 7402–5.
   PubMed Web of Science ®Google Scholar
• Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003). 2009; 49(Suppl 1): S16–29. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Byetta [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 29 January 2012].
   Google Scholar
• Bydureon [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 29 January 2012].
   Google Scholar
• Victoza [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 29 January 2012].
   Google Scholar
• Victoza [prescribing information]. Denmark: Novo Nordisk A/S.2012. April.
   Google Scholar
• Byetta [prescribing information]. San Diego CA: Amylin Pharmaceuticals.2011.
   Google Scholar
• Januvia [prescribing information]. Whitehouse Station NJ: Merck.2012. April.
   Google Scholar
• Tradjenta [prescribing information]. IngelheimGermany: Boehringer Ingelheim.2011. July.
   Google Scholar
• Onglyza [prescribing information]. Princeton NJ: Bristol-Myers Squibb.2011. December.
   Google Scholar
• Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: Physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008; 4: 355–62.
   PubMedGoogle Scholar
• Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother. 2003; 37: 1082–9. 10.3402/jchimp.v2i3.19081.
   Google Scholar
• Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther. 2009; 2: 203–14.
   Google Scholar
• Symlin [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 27 January 2012].
   Google Scholar
• Cycloset [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 30 January 2012].
   Google Scholar
• DeFronzo R. Bromocriptine: A sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011; 34: 789–94. 10.3402/jchimp.v2i3.19081.
   PubMed Web of Science ®Google Scholar
• Handelsman Y. Role of bile acid sequestrant in the treatment of type 2 diabetes. Diabetes Care. 2011; 34: S244–50. 10.3402/jchimp.v2i3.19081.
   Google Scholar
• Welchol [Internet]. Silver Spring. , Maryland: U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [cited 30 January 2012].
   Google Scholar